- Mindset Pharma (MSET) has been invited to present at the H.C. Wainwright “Psychedelics In Psychiatry and Beyond” virtual conference on June 17
- Mindset Pharma’s Board of Directors has approved a $113,000 debt settlement to a creditor
- Mindset will issue 176,562 common shares at a deemed price of $0.64 per share
- The company is launching an investor communications program with CDMG
- Mindset Pharma Inc. is a drug discovery and development company
- Mindset Pharma Inc. (MSET) is down 14.06 per cent, trading at C$0.55 per share at 10:45 am ET
Mindset Pharma (MSET) has been invited to present at the H.C. Wainwright “Psychedelics In Psychiatry and Beyond” virtual conference on June 17, 2021.
James Lanthier, CEO of Mindset, commented,
“Mindset is pleased to be invited to present at H.C. Wainwright’s conference. Mindset has expanded its next generation drug program to four distinct families of novel, patent-pending compounds with the goal of creating optimized therapeutics for a range of treatment modalities and indications. We are excited to share the Mindset story with a broader investor audience and thank H.C. Wainwright for the invitation.”
Mindset Pharma’s Board of Directors has approved a $113,000 debt settlement to a creditor of the company. Mindset is to issue 176,562 common shares at a deemed price of $0.64 per share. The share issuance in connection with the debt settlement is subject to approval from the Canadian Securities Exchange.
The company would also like to announce the launch of a new investor communications program. CDMG will develop and execute the program and provide marketing services focusing on North America.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
Mindset Pharma Inc. (MSET) is down 14.06 per cent, trading at C$0.55 per share at 10:45 am ET.